# Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

> **NCT04144608** · PHASE2 · COMPLETED · sponsor: **Yongchang Zhang** · enrollment: 40 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04144608
- **Lead sponsor:** Yongchang Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144608, "Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04144608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*